Investment opportunity in a promising medical device startup, MitrAssist Ltd. The company's proprietary, minimally invasive mitral valve implant meets a critical need. There are 1.6 million Americans patients suffering from mitral regurgitation (MR) -- and 50,000 new patients diagnosed each year -- who are not candidates for open heart surgery, today's standard treatment for acute MR. The market opportunity for the newly diagnosed cases in U.S alone is estimated at $1.5 billion. MitrAssist has completed a successful acute proof of concept and chronic evaluation and expects to complete chronic animal trials by end of Q1/2014. The Company seeks $600,000 to complete transapical chronic animal studies.